NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128173	Articles
104823	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 10/15/2024 at 12:30, 1 year 3 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
NanoViricides, Inc. announces interview with Dr. Diwan discussing revolutionary broad-spectrum antiviral clinical drug candidate NV-387 and innovative nanoviricide technology platform

NV-387 Clinical Trials NanoViricides Inc. Antiviral NanoViricides Technology
BRIEF

published on 10/08/2024 at 12:35, 1 year 4 months ago

NanoViricides to Address AMR Summit 2024 on Innovative Drug Technologies

Antimicrobial Resistance Clinical Trials AMR Summit 2024 NanoViricides Technology NV-387 Drug
BRIEF

published on 10/08/2024 at 12:35, 1 year 4 months ago

NanoViricides participera au Sommet AMR 2024 sur les technologies pharmaceutiques innovantes

Essais Cliniques Résistance Aux Antimicrobiens Sommet AMR 2024 Technologie Des Nanoviricides Médicament NV-387
PRESS RELEASE

published on 10/08/2024 at 12:30, 1 year 4 months ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to discuss NanoViricides' pathogen-directed attack technology combating AMR at the Global AMR Summit, highlighting the 'shape-shifting' nanoviricide platform

NanoViricides Antiviral AMR Nanomedicines Pathogen-directed Therapy
BRIEF

published on 09/30/2024 at 12:35, 1 year 4 months ago

NanoViricides Reports Annual Financials and Advances NV-387 to Phase II Trials

NanoViricides NV-387 Financial Report Antiviral Drug Phase II Trials
BRIEF

published on 09/30/2024 at 12:35, 1 year 4 months ago

NanoViricides publie ses résultats financiers annuels et fait progresser le NV-387 vers les essais de phase II

NanoViricides NV-387 Rapport Financier Médicament Antiviral Essais De Phase II
PRESS RELEASE

published on 09/30/2024 at 12:30, 1 year 4 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387

NanoViricides NV-387 Financial Updates Form 10-K Phase II Clinical Trials
BRIEF

published on 09/26/2024 at 12:35, 1 year 4 months ago

NanoViricides Signs Comprehensive Antiviral Drug Agreement With TheraCour Pharma

NanoViricides NV-387 Antiviral Drugs TheraCour Pharma Trojan Horse Drugs
BRIEF

published on 09/26/2024 at 12:35, 1 year 4 months ago

NanoViricides signe un accord global sur les médicaments antiviraux avec TheraCour Pharma

NanoViricides NV-387 Médicaments Antiviraux TheraCour Pharma Drogues Du Type Cheval De Troie
PRESS RELEASE

published on 09/26/2024 at 12:30, 1 year 4 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections

NV-387 Antiviral Drugs NanoViricides Inc. TheraCour Pharma Nanoviricide Technology

Accesswire

Published on 02/08/2026 at 21:00, 5 hours 56 minutes ago

Banyan Gold Extends Airstrip and High-Grade Mineralization to 350m Vertical Depth, Yukon, Canada
Published on 02/07/2026 at 01:00, 2 days 1 hour ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 2 days 3 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 2 days 4 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 2 days 11 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 1 day 5 hours ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 1 day 10 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 1 day 10 hours ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 2 days 7 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 2 days 9 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 2 days 8 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 2 days 8 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 2 days 10 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 2 days 10 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 19 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE